Mannose-binding lectin (MBL), a C-type lectin component of the human innate immune system, binds to the gp120 envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1). The objective of this study was to assess the effects of inhibitors of endoplasmic reticulum glucosidases and Golgi mannosidase as well as neuraminidase (NA) on the interaction between HIV and MBL. Production of HIV in the presence of the mannosidase I inhibitor deoxymannojirimycin (dMM) significantly enhanced binding of HIV to MBL and increased MBL neutralization of an M-tropic HIV primary isolate. In contrast, culturing HIV in the presence of α-glucosidase I and II inhibitors castanospermine and deoxynojirimycin only slightly affected virus binding and neutralization by MBL. Removal of sialic acid from HIV by NA also significantly enhanced virus binding and neutralization by MBL. Treatment of virus grown in the presence of dMM with endoglycosidase F1 substantially reduced binding to MBL, indicating that dMM increased MBL binding by increasing high-mannose carbohydrates on the virus. In contrast, endoglycosidase F1 did not decrease the MBL interaction with NA-treated virus, suggesting that NA exposed novel MBL binding sites. Treatment with dMM increased the immunocapture of HIV by monoclonal antibodies 2F5 and 2G12, indicating that altering the glycosylation of viral glycoproteins increases the accessibility or reactivity of some epitopes. This study shows that specific alterations of the N-linked carbohydrates on HIV gp120/gp41 can enhance MBL-mediated neutralization of virus by strengthening the interaction of HIV-1 with MBL.
BackN. K.,
SmitL.,
De JongJ. J.,
KeulenW.,
SchuttenM.,
GoudsmitJ.,
TersmetteM.1994; An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199:431–438
BaptistaJ. A.,
GossP.,
NghiemM.,
KrepinskyJ. J.,
BakerM.,
DennisJ. W.1994; Measuring swainsonine in serum of cancer patients: phase I clinical trial. Clin Chem 40:426–430
BarbasC. F.,
III BjorlingE.,
ChiodiF.& 8 others1992; Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci U S A 89:9339–9343
BlockT. M.,
LuX.,
MehtaA. S.7 other authors1998; Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med 4:610–614
ChildsR. A.,
DrickamerK.,
KawasakiT.,
ThielS.,
MizuochiT.,
FeiziT.1989; Neoglycolipids as probes of oligosaccharide recognition by recombinant and natural mannose-binding proteins of the rat and man. Biochem J 262:131–138
EzekowitzR. A.,
KuhlmanM.,
GroopmanJ. E.,
ByrnR. A.1989; A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus. J Exp Med 169:185–196
GrutersR. A.,
NeefjesJ. J.,
TersmetteM.,
de GoedeR. E.,
TulpA.,
HuismanH. G.,
MiedemaF.,
PloeghH. L.1987; Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature 330:74–77
HaurumJ. S.,
ThielS.,
JonesI. M.,
FischerP. B.,
LaursenS. B.,
JenseniusJ. C.1993; Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. AIDS 7:1307–1313
JackD. L.,
KleinN. J.,
TurnerM. W.2001; Mannose-binding lectin: targeting the microbial world for complement attack and opsonophagocytosis. Immunol Rev 180:86–99
KarpasA.,
FleetG. W.,
DwekR. A.,
PeturssonS.,
NamgoongS. K.,
RamsdenN. G.,
JacobG. S.,
RademacherT. W.1988; Aminosugar derivatives as potential anti-human immunodeficiency virus agents. Proc Natl Acad Sci U S A 85:9229–9233
LeonardC. K.,
SpellmanM. W.,
RiddleL.,
HarrisR. J.,
ThomasJ. N.,
GregoryT. J.1990; Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 265:10373–10382
MaY.,
ShidaH.,
KawasakiT.1997; Functional expression of human mannan-binding proteins (MBPs) in human hepatoma cell lines infected by recombinant vaccinia virus: post-translational modification, molecular assembly, and differentiation of serum and liver MBP. J Biochem 122:810–818
MalhotraR.,
WormaldM. R.,
RuddP. M.,
FischerP. B.,
DwekR. A.,
SimR. B.1995; Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1:237–243
MeansR. E.,
DesrosiersR. C.2000; Resistance of native, oligomeric envelope on simian immunodeficiency virus to digestion by glycosidases. J Virol 74:11181–11190
MehtaA.,
ZitzmannN.,
RuddP. M.,
BlockT. M.,
DwekR. A.1998; Alpha-glucosidase inhibitors as potential broad based anti-viral agents. FEBS Lett 430:17–22
MontefioriD. C.,
RobinsonW. E.Jr.,
MitchellW. M.1988; Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 85:9248–9252
MooreJ. P.,
WallaceL. A.,
FollettE. A.,
McKeatingJ. A.1989; An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. AIDS 3:155–163
MooreJ. P.,
SattentauQ. J.,
WyattR.,
SodroskiJ.1994; Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J Virol 68:469–484
MusterT.,
SteindlF.,
PurtscherM.,
TrkolaA.,
KlimaA.,
HimmlerG.,
RukerF.,
KatingerH.1993; A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67:6642–6647
NethO.,
JackD. L.,
DoddsA. W.,
HolzelH.,
KleinN. J.,
TurnerM. W.2000; Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 68:688–693
OhtaniK.,
SuzukiY.,
EdaS.7 other authors1999; High-level and effective production of human mannan-binding lectin (MBL) in Chinese hamster ovary (CHO) cells. J Immunol Methods 222:135–144
PurtscherM.,
TrkolaA.,
GruberG.,
BuchacherA.,
PredlR.,
SteindlF.,
TauerC.,
BergerR.,
BarrettN.,
JungbauerA.and others1994; A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 10:1651–1658
SaifuddinM.,
HartM. L.,
GewurzH.,
ZhangY.,
SpearG. T.2000; Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. J Gen Virol 81:949–955
SandersR. W.,
VenturiM.,
SchiffnerL.,
KalyanaramanR.,
KatingerH.,
LloydK. O.,
KwongP. D.,
MooreJ. P.2002; The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76:7293–7305
ScanlanC. N.,
PantophletR.,
WormaldM. R.7 other authors2002; The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1→2 mannose residues on the outer face of gp120. J Virol 76:7306–7321
TakefmanD. M.,
SullivanB. L.,
ShaB. E.,
SpearG. T.1998; Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis. Virology 246:370–378
TierneyM.,
PottageJ.,
KesslerH.other authors1995; The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and infectious Diseases. J Acquir Immune Defic Syndr Hum Retrovirol 10:549–553
TrkolaA.,
PurtscherM.,
MusterT.7 other authors1996; Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70:1100–1108
van EmmerikL. C.,
KuijperE. J.,
FijenC. A.,
DankertJ.,
ThielS.1994; Binding of mannan-binding protein to various bacterial pathogens of meningitis. Clin Exp Immunol 97:411–416
WalkerB. D.,
KowalskiM.,
GohW. C.,
KozarskyK.,
KriegerM.,
RosenC.,
RohrschneiderL.,
HaseltineW. A.,
SodroskiJ.1987; Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine. Proc Natl Acad Sci U S A 84:8120–8124
WyattR.,
KwongP. D.,
DesjardinsE.,
SweetR. W.,
RobinsonJ.,
HendricksonW. A.,
SodroskiJ. G.1998; The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705–711